	Paliperidone palmitate (Invega Sustenna)	Paliperidone palmitate (Invega Trinza)	Paliperidone Palmitate (Invega Hafyera)	Risperidone microspheres (Risperdal Consta)	Risperidone copolymer (Risperdal Perseris)	Olanzapine pamoate (Zyprexa Relprevv)	Aripiprazole monohydrate (Abilify Maintena)	Aripiprazole lauroxil (Aristada & Aristada Initio)	Fluphenazine decanoate (Prolixin Decanoate)	Haloperidol decanoate (Haldol Decanoate)
Dosing Conversion	39-78mg IM = 3mg/d PO 117mg IM = 6mg/d PO 156mg IM = 9mg/d PO 234mg IM = 12mg/d PO	78 = 273mg 117 = 410mg 156 = 546mg 234 = 819mg	*q1mo/q3mo = q6mo* 156/546 = 1092mg 234/819 = 1560mg	25mg IM = 2-4mg/d PO 37.5mg IM = 4-6mg/d PO 50mg IM = 6-8mg/d PO	90mg IM = 3mg PO 120mg IM = 4mg PO	See Maintenance Dosing below	400mg IM =10-20mg PO	441mg IM q4wk = 10mg PO 662mg q4wk/882mg q6wk/1064mg q8wk = 15mg PO 882mg IM q4wk = ≥20mg PO	25mg IM = 20mg PO	10-15X daily PO dose
Initial Dosing Schedule	Day 1: 234mg IM Day 8: 156mg IM *given as deltoid injections Day 35: give maintenance dose	Initiate after 4 months of treatment with Sustenna using conversion above.	Initiate after 4 months of treatment with Sustenna, 3 months of treatment with Trinza using conversion above.	12.5mg 25mg 37.5mg 50mg q2 wks	90mg or 120mg q4wks	Loading strategy given over 8 weeks: PO: 10mg; 15mg; 20mg IM: 210mg q2 wks x 4 doses or 405mg q4 wks x 2 doses; 300mg q2 wks x 4 doses; 300mg q2 wks x 4 doses	q4wks: 400mg IM 300mg IM if 2D6 poor metabolizer 200mg IM if 2D6 PM on strong 3A4 inhibitor	Aristada: 441mg IM q4wk; 662mg IM q4wk; 882mg IM q4wk or q6wk; 1064mg IM q8w Aristada Initio: 675mg IM x1 + aripiprazole 30mg PO x1 + 1st Aristada LAI dose (see left) within 10 days	Complete target IM dose on day 1	Divide target IM dose over 2 injections given 3 days apart
Maintenance Dosing Schedule	3mg/d PO / 39-78mg IM q4wk 6mg/d PO / 117mg IM q4wk 9mg/d PO / 156mg IM q4wk 12mg/d PO / 234mg IM q4wks *given as gluteal injections	Sustenna Dose / Trinza Dose: 78mg q4wk / 273mg q3mo 117mg q4wk / 410mg q3mo 156mg q4wk / 546mg q3mo 234mg q4wk / 819mg q3mo	Hafyera Dose: N/A N/A 1092mg q6mo 1560mg q6mo	Same as initial dosing schedule	Same as initial dosing schedule	PO: 10mg; 15mg; 20mg IM: 150mg q 2wks or 300mg q4wks; 210mg q2wks or 405mg q4wks; 300mg q2wks	400mg IM q4 wks Dose adjustment to maintenance dose: Strong 2D6 or 3A4 inhibitor added: 300mg / 200mg 2D6 & 3A4 inhibitor added: 200mg / 160mg 3A4 inducer added: Avoid use / Avoid use	Same as Aristada dosing regimen Dose adjustment to maintenance dose: Strong 3A4 inhibitor added: 441mg q4wk > no change; 662mg q4wk > 441mg q4wk; 882mg q4wk > 662mg q4wk; 882mg q6wk/1064mg q8wk > 441mg q4wk Poor Metabolizer 2D6 = reduce to 441mg q month Strong 2D6 inhibitor added: 441mg q4wk > no change; 662mg q4wk > 441mg q4wk; 882mg q4wk > 662mg q4wk; 882mg q6wk/1064mg q8wk > 441mg q4wk Poor Metabolizer 2D6 = no change 2D6 & 3A4 inhibitor added: 441mg q4wk > no change if tolerated; Avoid use at all other doses 3A4 inducer added: 441mg q4wk > 662mg q 4 wk; No change for all other doses	Complete IM dose q3 wks	Complete IM dose q4 wks
"Loading" Strategy	Same as standard titration	N/A	N/A	None	None	Same as standard titration	None	None	None	20X target daily PO dose given in 100mg doses q3-7 days. Decrease subsequent IM doses by 25% q4wks until target monthly dose attained
PO Coverage Required	None	None	None	Full PO dose x 3 weeks, then d/c vs. taper (e.g., by 1mg/wk)	None	None	Full PO dose x 2 weeks, then d/c vs taper	Full PO dose x 21 days, then d/c vs taper No PO coverage for Aristada Initio	Full PO dose x 3 weeks, ½ PO dose x 3 weeks, then stop	Full PO dose x 4 weeks, ½ PO dose x 4 weeks, then stop
Dosing window	+/- 7 days before or after due date	+/- 14 days before or after due date	up to 2 weeks before or 3 weeks after due date	no information	no information	no information	2 days before or up to 7 days after due date (≥7 days PO supplementation should be given)	up to 14 days before due date, ASAP after due date (≥2 to 4 weeks after due date PO supplementation is required depending on dose and frequency)		
Tmax	13-14 days deltoid 13-17 days gluteal	24-34 days deltoid 23 -31 days gluteal	29-32 days	4.5 weeks	2 peaks: 4-6h , 10-14d RPD 4-48h, 7-11d 9-OH RPD	7 days	7.1 days deltoid 24.1 days gluteal	24.4-35.2 days	1 day	6 days
T1/2	25-49 days	45-82 days (both sites) 56.9 days deltoid 68.5 days gluteal	148-159 days	3-6 days	9-11 days RPD 8-9 days 9-OH RPD	30 days	17.8±7.45 days deltoid 24±7.36 days gluteal	53.9-57.2 days	14-26 days	3 weeks
Time to Steady-state	8-9 months	?		6 weeks	60 days	3 months	16 weeks	16 weeks	3 months	3-4 months
Injection Type	Deltoid in loading, then gluteal IM	Deltoid or gluteal IM	Gluteal IM	Deltoid or gluteal IM	Subcutaneous	Gluteal IM	Deltoid or gluteal IM	Deltoid (441mg only) or gluteal IM	Z-track IM (deltoid or gluteal)	Z-track IM (deltoid or gluteal)
Comments	Converting RPD to PAL (estimated): RPD 2 = PAL 3 (mg) RPD 4 = PAL 6 RPD 6 = PAL 9 RPD 8 = PAL 12	For use after having received Invega Sustenna for 4 months	For use after having received Invega Sustenna for 4 months or Trinza for 3 months	1% of medication released on injection; release of medication occurs weeks 4-6 as microspheres degrade	Atrigel™ dose delivery system	Post-injection Delirium Sedation Syndrome (PDSS) 1-3h post-injection; Sx resemble olanzapine OD; Requires registration in program, patients must be monitored on-site ≥ 3h after injection	Given long $t_{1/2}$ of aripiprazole it is best to try PO for 2 weeks to fully assess tolerability	Given long $t_{1/2}$ of aripiprazole it is best to try PO for 2 weeks to fully assess tolerability	Also given q2 weeks	Do not exceed 3mL per injection site

Good review article: PMID 29569082, Erratum PMID: 29858836 & @ Current Psychiatry 2020
Good web resource: smiadviser.org